Oritavancin: A potential weapon in the battle against serious Gram-positive pathogens

Future Microbiology

Volumn 3, Issue 3, 2008, Pages 251-263

  Crandon, Jared ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

Glycopeptide; LY333328; Oritavancin; Staphylococcus aureus; Vancomycin resistant Enterococcus

Indexed keywords

CEFALEXIN; CEFTRIAXONE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DEXAMETHASONE; GENTAMICIN; LINEZOLID; ORITAVANCIN; PLACEBO; TEICOPLANIN; VANCOMYCIN; ANTIINFECTIVE AGENT; GLYCOPEPTIDE;

ABSCESS; AEROBIC BACTERIUM; ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANXIETY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BACTEREMIA; BACTERIAL MENINGITIS; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BIOFILM; BOLUS INJECTION; CATHETER INFECTION; CELL LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRY SKIN; ENDOCARDITIS; ENTEROCOCCUS; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; HUMAN; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; INFECTION COMPLICATION; INJECTION SITE PHLEBITIS; INJECTION SITE REACTION; INJECTION SITE THROMBOSIS; INSOMNIA; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NAUSEA AND VOMITING; NONHUMAN; PAIN; PNEUMONIA; POSTANTIBIOTIC EFFECT; PRIORITY JOURNAL; PRURITUS; RHINITIS; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; TIME TO MAXIMUM PLASMA CONCENTRATION; BACTERIAL INFECTION; COMPARATIVE STUDY; DRUG EFFECT; HALF LIFE TIME; REVIEW; SOFT TISSUE INFECTION; TREATMENT OUTCOME;

ENTEROCOCCUS; POSIBACTERIA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS;

ANTI-BACTERIAL AGENTS; BACTEREMIA; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HALF-LIFE; HUMANS; SOFT TISSUE INFECTIONS; TREATMENT OUTCOME;

EID: 46049091025     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460913.3.3.251     Document Type: Article

References (65)

1. Cosgrove S, Carmeli Y: The impact of antimicrobial resistance on health and economic outcomes. Clin. Infect. Dis. 36, 1433-1437 (2003).
2. Carmeli Y, Elopoulos G, Mozaffari E, Samore M: Health and economic outcomes of vancomycin-resistant enterococci. Arch. Intern. Med. 162, 2223-2228 (2002).
3. Stosor V, Peterson LR, Postelnick M, Noskin GA: Enterococcus faecium bacteremia: does vancomycin resistance make a difference? Arch. Intern. Med. 158, 522-527 (1998).
4. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control 32, 470-485 (2004).
5. Appelbaum PC: The emergence of vancomycin-intermediate and vancomycin-resistant Staphylacoccus aureus. Clin. Microbiol. Infect. 12(S1), 16-23 (2006).
6. Spellberg B, Guidos R, Gilbert D et al.: The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. 46, 155-164 (2008).
7. Lu W, Oberthur M, Leimkuhler C et al.: Characterization of a region specific epivancosaminyl transferase GtfA and enzymatic reconstitution of the antibiotic chloroeremomycin. Proc. Natl Acad. Sci. 101, 4390-4395 (2004).
8. Allen N, Nicas T: Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol. Rev. 26, 511-532 (2003).
9. Cooper R, Snyder N, Zweifel M et al.: Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity. J. Antibiotics 49, 575-581 (1996).
10. Kim SJ, Cegelski L, Stueber D et al.: Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus. J. Mol. Biol. 377(1), 281-293 (2008).
11. Wang T-SA, Kahne DE, Walker S: Probing the mechanism of inhibition of bacterial peptidoglycan glycotransferases by glycopeptide analogs. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts. American Society for Microbiology, Chicago, IL, USA, 17-20 September, 2007. (Abstract C1-1474).
12. McKay G, Fadhil I, Beaulieu S et al.: Oritavancin disrupts transmembrane potential and membrane integrity concomitantly with cell killing in Staphylococcus aureus and vancomycin-resistant enterococci. Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts. American Society for Microbiology, San Francisco, CA, USA, 17-20 September, 2006. (Abstract C1-682).
13. Garcia-Garrote F, Cercenado E, Alcala L, Bouza E: In vitro activity of the new glycopeptide LY333328 against multiply resistant Gram-positive clinical isolates. Antimicrob. Agents Chemother. 42, 2452-2455 (1998).
14. O'Connor R, Baines S, Freeman J, Wilcox M: In vitro susceptibility of genotypically distinct Clostridium difficile strains to oritavancin. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts. American Society for Microbiology, Chicago, IL, USA, 17-20 September, 2007. (Abstract E-1618).
15. Arhin F, Sarmiento I, Bailey A et al.: Activity of oritavancin against drug-resistant S. aureus in the presence of polysorbate-80. Presented at: 47th Interscience Conterence on Antimicrobial Agents and Chemotherapy Abstracts. American Society for Microbiology, Chicago, IL, USA, 17-20 September, 2007. (Abstract D-242).
16. Sahm DF, Arhin FF, Moeck G, Draghi D: In vitro activity profile of oritavancin against resistant staphylococcal populations from a recent surveillance initiative. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts. American Society for Microbiology, Chicago, IL, USA, 17-20 September, 2007. (Abstract E-1617).
17. Draghi DC, Grover PK, Moeck G et al.: In vitro activity profile of oritavancin (ORI) against organisms demonstrating key resistance profiles to other antimicrobial agents. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts. American Society for Microbiology, Chicago, IL, USA, 17-20 September, 2007. (Abstract E-1613).
18. Draghi DC, Sahm DF, Arhin FF, Moeck G: Anti-streptococcal activity profile of oritavancin, a potent lipoglycopeptide under development for use against Gram-positive infections. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts. American Society for Microbiology Chicago, IL, USA, 17-20 September, 2007. (Abstract E-1616).
19. Draghi D, Sahm, DF, Arhin FF, Moeck G: Anti-enterococcal activity profile of oritavancin, a potent lipoglycopeptide under development for use against Gram-positive infections. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts. American Society for Microbiology, Chicago, IL, USA, 17-20 September, 2007. (Abstract E-1615).
20. Moeck G, Draghi D, Arhin F, Sahm D: In vitro activity profile of oritavancin against a broad spectrum of aerobic and anaerobic bacterial pathogens. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts. American Society for Microbiology, Chicago, IL, USA, 17-20 September, 2007. (Abstract E-1612).
21. Arhin F, Sarmiento I, Parr T, Moeck G: Effect of polysorbate-80 on oritavancin binding to plastic surfaces - implication for susceptibility testing. Antimicrob. Agents Chemother. DOI: 10.1128/AAC.01513-07 (2008) (Epub ahead of print).
22. Arhin F, Sarmiento I, Bailey A, McKay G: Influence of polysorbate-80 on susceptibility of Gram-positive bacteria to oritavancin. Presented at: 17th European Congress of Clinical Microbiology and Infectious Diseases Abstracts. European Society of Clinical Microbiology and Infectious Diseases, Munich, Germany, March 31-April 4, 2007. (Abstract P827).
23. Clinical and Laboratory Standards Institute: Performance Standard for Antimicrobial Susceptibility Testing. Seventeenth Informational Supplement. CLSI document M100-S18. CLSI, PA, USA (2008).
24. Bozdogan B, Esel D, Whitener C et al.: Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J. Antimicrob. Chemother. 52, 864-868 (2003).
25. Kaatz G, Seo S, Aeschlimann J et al.: Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 42, 981-983 (1998).
26. Saleh-mghir A, Lefort A, Petegnief Y et al.: Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis. Antimicrob. Agents Chemother. 43, 115-120 (1999).
27. Lefort A, Saleh-mghir A, Garry L et al.: Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis. Antimicrob. Agents Chemothe. 44, 3017-3021 (2000).
28. Rupp M, Fey P, Longo M: Effect of LY333328 against vancomycin-resistant Enterococcus faecium in a rat central venous catheter-associated infection model. J. Antimicrob. Chemother. 47, 705-707 (2001).
29. Gerber J, Smirnow A, Wellmer A et al.: Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin. Antimicrob. Agents Chemother. 45, 2169-2172 (2001).
30. Cabellos C, Fernandez A, Maiques J et al.: Experimental study of ly333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis. Antimicrob. Agents Chemother. 47, 1907-1911 (2003).
31. Lehoux D, Okusanya O, Ostiguy V et al.: PK-PD of oritavancin against S. pneumoniae in a murine-pneumonia infection model. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts. American Society for Microbiology, Chicago, IL, USA, 17-20 September, 2007. (Abstract A-49).
32. Bhavnani S, Rubino C, Forrest A et al.: Use of PK-PD principles to guide clinical drug development for oritavancin. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts. American Society for Microbiology, Chicago, IL, USA, 17-20 September, 2007. (Abstract A-51).
33. Chien J, Allerheiligen S, Phillips D et al.: Safety and pharmacokinetics of single intravenous doses of ly333328 diphosphate (glycopeptide) in healthy men. Presented at: 38th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts. American Society for Microbiology, San Diego, CA, USA, 24-27 September, 1998. (Abstract A-55).
34. De la Pena A, Chien J, Geiser J et al.: Microbiological outcomes and pharmacokinetics of oritavancin in patients with Gram-positive bacteremia. Presented at: 12th European Congress of Clinical Microbiology and Infectious Diseases Abstracts. European Society of Clinical Microbiology and Infectious Diseases, Milan, Italy, 21-24 April, 2002. (Abstract P1091).
35. Bhavnani S, Owen J, Loutit J et al.: Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Diag. Microbiol. Infect. Dis. 50, 95-102 (2004).
36. Fetterly G, Ong C, Bhavnani S et al.: Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram, dose for 3 days or a single 800-milligram dose. Antimicrob. Agents Chemother. 49, 148-152 (2005).
37. Braun D, Chien J, Rarlow D et al.: Oritavancin (LY333328): a dose-escalation safety and pharmacokinetics study in patients. Presented at: 11th European Congress of Clinical Microbiology and Infectious Diseases Abstracts. European Society of Clinical Microbiology and Infectious Diseases, Istanbul, Turkey 1-4 April, 2001.
38. Rowe PA, Brown TJ: Protein binding of 14C-oritavancin. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts. American Society for Microbiology, Chicago, IL, USA, 16-19 December, 2001. (Abstract A-2193).
39. Van Bambeke F, Carryn S, Snoeck A et al.: LY333328 (oritavancin) glycopeptide accumulates in cultured macrophages but is only bacteriostatic towards intracellular Listeria monocytogenes. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts. American Society for Microbiology, Chicago, IL, USA, 16-19 December, 2001. (Abstract A-2069).
40. Van Bambeke F, Snoeck A, Chanteux et al.: Is LY33328 glycopeptide a new cell-associated antibiotic? Comparative studies with vancomycin and azithromycin in a model of J774 mouse macrophages. Presented at: 11th European Congress of Clinical Microbiology and Infectious Diseases Abstracts. European Society of Clinical Microbiology and Infectious Diseases, Istanbul, Turkey 1-4 April, 2001.
41. Seral C, Van Bambeke F, Tulkens P: Activity of the new glycopeptide oritavancin (LY333328) in a model of Staphylococcus aureus intraphagocytic infection in comparison with telithromycin (TEL) and moxifloxacin (MXF). Presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts. American Society for Microbiology, San Diego, CA, USA, 27-30 September, 2002. (Abstract A-483).
42. Barcia-Macay M, Seral C, Mingeot-Leclercq M et al.: Comparative activity of 12 antibiotics (abx) used at clinically-meaningful extracellular concentration against S. aureus in broth and in human thp-1 macrophages. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts. American Society for Microbiology, Chicago, IL, USA 14-17 September, 2003. (Abstract A-1174).
43. Rodvold K, Gotfried M, Loutit J, Porter S: Plasma and intrapulmonary concentrations of oritavancin and vancomycin in normal healthy adults. Presented at: 14th European Congress of Clinical Microbiology and Infectious Diseases Abstracts. European Society of Clinical Microbiology and Infectious Diseases, Prague/Czech Republic 1-4 May, 2004. (Abstract O254).
44. Fetterly G, Owen J, Bhavnani S et al.: Effect of hepatic impairment on the pharmacokinetics of the novel glycopeptide oritavancin. Presented at: The American Association of Pharmaceutical Scientists Annual Meeating Abstracts. The American Association of Pharmaceutical Scientists, Baltimore, MD, USA, 7-10 November, 2004. (Abstract T3313).
45. Mercier R, Houlihan H, Rybak M: Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococus aureus and Enterococcus faecium. Antimicrob, Agents Chemother. 41, 1307-1312 (1997).
46. Biavasco F, Vignaroli C, Lupidi R et al.: In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide. Antimicrob. Agents Chemother. 41, 2165-2172 (1997).
47. Zelenitsky S, Karlowsky J, Zhanel G et al.: Time-kill curves for a semisynthetic glycopeptide, LY333328, against vancomycin-susceptible and vancomycin-resistant Enterococcus faecium strains. Antimicrob. Agents Chemother. 41, 1407-1408 (1997).
48. Coyle E, Rybak M: Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 45, 706-709 (2001).
49. Sahm D, Blosser R, Loutit J, Porter S: Oritavancin time-kill, time-kill synergy, and postantibiotic effect determinations with S. aureus and enterococci. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts. American Society for Microbiology, Chicago, IL, USA, 14-17 September, 2003. (Abstract A-1170).
50. McKay G, Beaulieu S, Belley A et al.: In vitro time kill studies of oritavancin against drug-resistant isolates of Staphylococcus aureus and Enterococci, Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts. American Society for Microbiology, Chicago, IL, USA, 17-20 September, 2007. (Abstract E-1614).
51. Boylan CJ, Campanale K, Iversen PW et al.: Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection. Antimicrob. Agents Chemother. 47, 1700-1706 (2003).
52. Rupp M, Ulphani J: Efficacy of LY333328 in a rat model of Staphylococcus aureus (SA) central venous catheter (CVC)-associated infection. Presented at: 38th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts. American Society for Microbiology, San Diego, CA, USA, 24-27 September, 2008. (Abstract F-111).
53. Lehoux D, Okusanya O, Ostiguy V et al.: PK-PD of oritavancin against S. pneumoniae in a musine-pneumonia infection model. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts. American Society for Microbiology, Chicago, IL, USA, 17-20 September, 2007. (Abstract A-49).
54. Lefort AA, Saleh-Jghir A, Garry L, Carbon C, Fantin B: Activity of LY333328 combined with gentamicin in vitro and in vivo in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis. Antimicrob. Agents Chemother. 44, 3017-3021 (2000).
55. Bhavnani S, Passarell J, Owen J et al.: Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 50, 994-1000 (2006).
56. Lin G, Creditc, K, Ednie L, Appelbaum P: Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob. Agents Chemother. 49, 770-772 (2005).
57. Aeschlimann J, Allen G, Hershberger E, Rybak M: Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model Antimicrob. Agents Chemother. 44, 2991-2998 (2000).
58. Baltch A, Smith R, Ritz W, Bopp L: Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium. Antimicrob. Agents Chemother. 42, 2564-2568 (1998).
59. McKay G, Beaulieu S, Parr T Jr, Moeck G: In vitro post antibiotic effect studies of oritavancin against S. aureus and enterococci. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts. American Society for Microbiology, Chicago, IL, USA, 17-20 September, 2007. (Abstract A-50).
60. Belley A, McKay G, Beaulieu S et al.: Oritavancin kills Staphylococcus aureus in slow-growing planktonic and biofilm states. Presented at: 46th Interscience Conference an Antimicrobial Agents and Chemotherapy Abstracts. American Society for Microbiology, San Francisco, CA, USA, 17-20 September, 2006. (Abstract B-0661).
61. Belley A, Neesham-Grenon E, Parr T Jr, Moeck G: Pharmacokinetic concentrations of oritavancin kill stationary-phase and biofilm Staphylococcus aureus in vitro. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts. American Society for Microbiology, Chicago, IL, USA, 17-20 September, 2007. (Abstract E-1620).
62. Wasilewski M, Disch D, McGill J et al.: Equivalence of shorter course therapy with oritavancin vs. vancomycin/cephalexin in complicated skin/skin structure infections. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts. American Society for Microbiology, Chicago, IL, USA, 16-19 December, 2001. (Abstract UL-18).
63. Giamarellou G, O'Riordan W, Harris H, et al.: Phase 3 trial comparing 3-7 days of oritavancin vs. 10-14 days of vancomycin/ cephalexin in the treatment of patients with complicated skin and skin structure infections. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts. American Society for Microbiology, Chicago, IL. USA 14-17 September, 2003. (Abstract L-739a).
64. Loutit J, O'Riordan W, San Juan J et al.: Phase 2 trial comparing four regimens of oritavancin vs. comparator in the treatment of patients with S. aureus bacteremia. Presented at: 14th European Congress of Clinical Microbiology and Infectious Diseases Abstracts. European Society of Clinical Microbiology and Infectious Diseases, Prague/Czech Republic, 1-4 May, 2004. (Abstract P541).
65. Van Bambeke F, Saffran J, Mingeot-Leclercq MP, Tulkens P: Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation. Antimicrob. Agents Chemother. 49, 1695-1700 (2005).